Oncotelic Therapeutics, Inc. announced that it has entered into a securities purchase agreement pursuant to which company issued a convertible promissory note to returning investor Mast Hill Fund, L.P., a fund managed by Mast Hill Management, LLC for gross proceeds of $544,500 on May 27, 2022. The note is convertible into shares of the company's common stock, par value $0.01 per share. The principal amount of the note is $605,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.036 USD | -7.69% | -8.63% | -6.01% |
1st Jan change | Capi. | |
---|---|---|
-6.01% | 14.39M | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.66% | 22.27B | |
-12.64% | 22.22B | |
-5.20% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. announced that it has received $0.5445 million in funding from Mast Hill Management, LLC